577978-57-5

Upstream product

• 68-12-2 N,N-dimethyl-formamide 
• 299916-62-4 7-N-benzyloxymethyl-9-bromo-9-deaza-6-O-methylhypoxanthine 

Downstream Products

• 1010701-21-9 diethyl (2S,3R)-2-hydroxy-3-({[5-benzyloxymethyl-4-methoxy-5H-pyrrolo[3,2-d]pyrimidin-7-yl]methyl}amino)butanedioate 
• 1010701-24-2 (S)-N-benzyl-1-(5-(benzyloxymethyl)-4-methoxy-5H-pyrrolo[3,2-d]pyrimidin-7-yl)-N-((2,2-dimethyl-1,3-dioxolan-4-yl)methyl)methanamine 
• 1124327-68-9 5-benzyloxymethyl-7-({[1,3-dihydroxy-2-(hydroxymethyl)propan-2-yl]amino}methyl)-4-methoxy-5H-pyrrolo[3,2-d]pyrimidine 
• 1010701-34-4 5-(benzyloxymethyl)-7-{[(1,3-dihydroxypropan-2-yl)amino]methyl}-4-methoxy-5H-pyrrolo[3,2-d]pyrimidine 
• 1010701-42-4 5-(benzyloxymethyl)-7-({[(4R)-2,2-dimethyl-1,3-dioxolan-4-yl](2-hydroxyethyl)amino}methyl)-4-methoxy-5H-pyrrolo[3,2-d]pyrimidine 
• 1010701-44-6 diethyl (2R,3S)-2-hydroxy-3-({[5-benzyloxymethyl-4-methoxy-5H-pyrrolo[3,2-d]pyrimidin-7-yl]methyl}amino)butanedioate 
• 1010701-46-8 diethyl 2-hydroxy-3-({[5-benzyloxymethyl-4-methoxy-5H-pyrrolo[3,2-d]pyrimidin-7-yl]methyl}amino)butanedioate 
• 1010701-48-0 diethyl 2-hydroxy-3-({[5-benzyloxymethyl-4-methoxy-5H-pyrrolo[3,2-d]pyrimidin-7-yl]methyl}amino)butanedioate 
• 1010701-51-5 5-benzyloxymethyl-7-[({[(4S,5R)-5-(hydroxymethyl)-2,2-dimethyl-1,3-dioxolan-4-yl]methyl}amino)methyl]-4-methoxy-5H-pyrrolo[3,2-d]pyrimidine 
• 1373335-80-8 (2S,3R,4R,5S)-3,4-bis(benzyloxy)-5-(benzyloxymethyl)-2-(hydroxymethyl)-N-(7-(benzyloxymethyl)-6-methoxy-9-deazapurin-9-yl)methylpyrrolidine 
• 1373335-83-1 (2S,3R,4R,5S)-3,4-bis(benzyloxy)-5-(benzyloxymethyl)-2-(fluoromethyl)-N-(7-(benzyloxymethyl)-6-methoxy-9-deazapurin-9-yl)methylpyrrolidine 
• 915227-41-7 C₁₇H₁₇N₃O₃ 
• 915227-40-6 C₁₇H₁₉N₃O₃ 
• 915227-42-8 C₂₂H₂₈N₄O₄ 

Relevant academic research and scientific papers

INHIBITORS OF NUCLEOSIDE PHOSPHORYLASES AND NUCLEOSIDASES

The present invention relates to compounds of the general formula (I) which are inhibitors of purine nucleoside phosphorylases (PNP), purine phosphoribosyltransferases (PPRT), 5'-methylthioadenosine phosphorylases (MTAP), 5'-methylthioadenosine nucleosida

INHIBITORS OF NUCLEOSIDE PHOSPHORYLASES AND NUCLEOSIDASES

The present invention relates to compounds of the general formula (I) which are inhibitors of purine muclioside phosphorylases (PNP), purine phosphoribosyltransferases (PPRT), 5'-methylthioadenosine phosphorylases (MTAP), 5'-methylthioadenosine mucliosidases (MTAN) and/or nucleoside hydrolases (NH). The invention also relates to the use of these compounds in the treatment of diseases and infections including cancer, bacterial infections, protozoal infections, and T-cell mediated disease and to pharmaceutical compositions containing the compounds

Exploring structure-activity relationships of transition state analogues of human purine nucleoside phosphorylase

The aza-C-nucleosides, Immucillin-H and Immucillin-G, are transition state analogue inhibitors of purine nucleoside phosphorylase, a therapeutic target for the control of T-cell proliferation. Immucillin analogues modified at the 2′-, 3′-, or 5′-positions of the azasugar moiety or at the 6-, 7-, or 8-positions of the deazapurine, as well as methylene -bridged analogues, have been synthesized and tested for their inhibition of human purine nucleoside phosphorylase. All analogues were poorer inhibitors, which reflects the superior capture of transition state features in the parent immucillins.